Pravastatin promotes coronary collateral circulation in patients with coronary artery disease

Coronary Artery Disease

Volumn 13, Issue 7, 2002, Pages 377-381

  Nishikawa, Hiroaki ^a   Miura, Shin Ichiro ^a   Zhang, Bo ^a   Shimomura, Hideki ^b   Arai, Hidekazu ^b   Tsuchiya, Yoshihiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Fukuoka Tokusyukai Hospital   (Japan)

Author keywords

Collateral circulation; Statin; Stenosed vessels

Indexed keywords

PRAVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; PLEIOTROPY; PRIORITY JOURNAL; SCORING SYSTEM;

AGED; ANTICHOLESTEREMIC AGENTS; COLLATERAL CIRCULATION; CORONARY CIRCULATION; CORONARY DISEASE; FEMALE; HUMANS; MALE; PRAVASTATIN;

EID: 0036873875     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200211000-00005     Document Type: Article

References (29)

1. Kastelein JJ. The future of best practice. Atherosclerosis 1999; 143(suppl 1):S17-S21.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
4. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21:1712-1719.
5. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 1999; 99:3227-3333.
6. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6:1004-1010.
7. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108:399-405.
8. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108:391-397.
9. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285:430-436.
10. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105:691-696.
11. Saku K, Zhang B, Ohta T, Arakawa K. Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. J Am Coll Cardiol 1999; 33:436-443.
12. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985; 5:587-592.
13. Saku K, Zhang B, Shirai K, Jimi S, Yoshinaga K, Arakawa K. Hyperinsulinemic hypoalphalipoproteinemia as a new indicator for coronary heart disease. J Am Coll Cardiol 1999; 34:1443-1451.
14. SAS/STAT user's guide. Version 6, Vol. 2, 4th ed. Cary, NC: SAS Institute; 1990.
15. Helfant RH, Vokonas PS, Gorlin R. Functional importance of the human coronary collateral circulation. N Engl J Med 1971; 284:1277-1281.
16. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999; 99:2871-2875.
17. Gorge G, Schmidt T, Ito BR, Pantely GA, Schaper W. Microvascular and collateral adaptation in swine hearts following progressive coronary artery stenosis. Basic Res Cardiol 1989; 84:524-535.
18. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 2001; 49:543-553.
19. Shyy YJ, Hsieh HJ, Usami S, Chien S. Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium. Proc Natl Acad Sci USA 1994; 91:4678-4682.
20. Arras M, Strasser R, Mohri M, Doll R, Eckert P, Schaper W, et al. Tumor necrosis factor-alpha is expressed by monocytes/macrophages following cardiac microembolization and is antagonized by cyclosporine. Basic Res Cardiol 1998; 93:97-107.
21. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001; 21:1327-1332.
22. Rasmussen LM, Hansen PR, Nabipour MT, Olesen P, Kristiansen MT, et al. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J 2001; 360:363-370.
23. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394:485-490.
24. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84:9265-9269.
25. Radomski MW, Rees DD, Dutra A, Moncada S. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 1992; 107:745-749.
26. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774-1777.
27. Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15:1652-1659.
28. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105:739-745.
29. van Vliet AK, van Thiel GC, Huisman RH, Moshage H, Yap SH, Cohen LH. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochem Biophys Acta 1995; 1245:105-111.